CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Identification of the more primitive CD34+ population within the myeloid BP-CML samples highlighted the discriminatory effect of nilotinib alone (healthy: 5.28 ± 3.13% cell death; BP-CML: 44.95 ± 12.44%; p = 0.0005), with VEN (healthy: 21.43 ± 10.8%; BP-CML: 67.79 ± 13.63%; p < 0.0001), with S63845 (healthy: 38.25 ± 18.58%; BP-CML: 67.35 ± 10.56%; p = 0.013), and with A-1331852 (healthy: 16.15 ± 6.02%; BP-CML: 64.27 ± 14.26%; p < 0.0001) compared with the healthy donor samples, while these distinctions could not be made within the CD34− population (Fig. 8B).